The global antimicrobial susceptibility testing market size is evaluated at USD 3.83 billion in 2025 and is forecasted to hit around USD 6.5 billion by 2034, growing at a CAGR of 6.06% from 2025 to 2034. The North America market size accounted for USD 1.52 billion in 2024 and is expanding at a CAGR of 6.15% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Antimicrobial Susceptibility Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Antimicrobial Susceptibility Testing Market, by Product Type, 2024-2034
8.1.1 Manual Products
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Automated Products
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Consumables
8.1.3.1. Market Revenue and Forecast (2021-2034)
9.1. Antimicrobial Susceptibility Testing Market, by Method Type, 2024-2034
9.1.1. ETEST
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Disks Diffusion
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Rapid Automation Method
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2034)
10.1. Antimicrobial Susceptibility Testing Market, by End User, 2024-2034
10.1.1. Hospitals & Diagnostic Laboratories
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Pharmaceutical & Biotechnology Companies
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.1.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.1.3. Market Revenue and Forecast, by End User (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.2.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.2.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.3.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.3.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.4.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End User (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End User (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.5.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.5.3. Market Revenue and Forecast, by End User (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End User (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product Type (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Method Type (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End User (2021-2034)
12.1. Accelerate Diagnostics, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Becton, Dickinson and Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Biomerieux SA
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Bio-Rad Laboratories, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bruker
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Danaher Corporation (Beckman Coulter)
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. F. Hoffmann-La Roche AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. HiMedia Laboratories
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Merck KGaA (MilliporeSigma)
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Thermo Fisher Scientific
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample